<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>More than 50 million Muslims throughout the world with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) fast for one lunar month (Ramadan) each year </plain></SENT>
<SENT sid="1" pm="."><plain>Health care providers within and outside the Muslim world need to be aware of the nature of these partial days of fasting and their risks (and potential benefits) to people with T2DM, and need to provide Ramadan-adjusted <z:mp ids='MP_0002055'>diabetes</z:mp> care </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0001943'>Hypoglycemia</z:hpo> during the fasting days represents the greatest health risk for these patients; hence, <z:mp ids='MP_0002055'>diabetes</z:mp>-related pharmacotherapy needs to be tailored and adjusted with this risk in mind </plain></SENT>
<SENT sid="3" pm="."><plain>With limited trial data available, this review proposes practical modifications to the usual pre-Ramadan <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> regimens that are based on pathophysiological principles, clinical trial evidence (where available), expert opinion, and extended practical experience </plain></SENT>
<SENT sid="4" pm="."><plain>Individualization of care is paramount in this regard to take into consideration the patient and societal, cultural, and economic variables </plain></SENT>
</text></document>